Medical News |
- Support for progranulin role in bipolar disorder
- EGFR–TKI tumour response predicts NSCLC survival
- EGFR–TKI tumour response predicts NSCLC survival
- Support for progranulin role in bipolar disorder
- Psychotherapies have specific effects on psychosis symptoms
- Psychotherapies have specific effects on psychosis symptoms
- Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC
- Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC
| Support for progranulin role in bipolar disorder Posted: 19 Feb 2014 04:00 PM PST Researchers have found reduced levels of plasma progranulin in patients with bipolar disorder, strengthening evidence for its possible role as a biomarker for the condition. |
| EGFR–TKI tumour response predicts NSCLC survival Posted: 19 Feb 2014 04:00 PM PST A partial or complete response to epidermal growth factor receptor tyrosine kinase inhibitor therapy is significantly associated with survival in patients with non-small-cell lung cancer, research suggests. |
| EGFR–TKI tumour response predicts NSCLC survival Posted: 19 Feb 2014 04:00 PM PST A partial or complete response to epidermal growth factor receptor tyrosine kinase inhibitor therapy is significantly associated with survival in patients with non-small-cell lung cancer, research suggests. |
| Support for progranulin role in bipolar disorder Posted: 19 Feb 2014 04:00 PM PST Researchers have found reduced levels of plasma progranulin in patients with bipolar disorder, strengthening evidence for its possible role as a biomarker for the condition. |
| Psychotherapies have specific effects on psychosis symptoms Posted: 19 Feb 2014 04:00 PM PST There are small but robust differences in the effects of different psychotherapies on psychosis symptoms, say the authors of a meta-analysis. |
| Psychotherapies have specific effects on psychosis symptoms Posted: 19 Feb 2014 04:00 PM PST There are small but robust differences in the effects of different psychotherapies on psychosis symptoms, say the authors of a meta-analysis. |
| Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC Posted: 18 Feb 2014 04:00 PM PST Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. |
| Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC Posted: 18 Feb 2014 04:00 PM PST Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment